Amifostine has the potential to induce haematologic responses and decelerate disease progression in individual patients with low- and intermediate-1-risk myelodysplastic syndromes

Leukemia Research

Volumn 33, Issue 9, 2009, Pages 1183-1188

  Schanz, Julie ^a   Jung, Heike ^a   Wörmann, Bernhard ^b   Gassmann, Winfried ^c   Petersen, Thomas ^b   Hinke, Axel ^d   Haase, Detlef ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b KLINIKUM BRAUNSCHWEIG   (Germany)

^c St Marien Krankenhaus Siegen gem GmbH   (Germany)

^d WiSP Wissenschaftlicher Service Pharma GmbH   (Germany)

Author keywords

Amifostine; Clinical trials; Cytogenetics; Intramedullary apoptosis; MDS; Randomized phase II study

Indexed keywords

AMIFOSTINE;

AGED; ARTHRALGIA; ARTICLE; BLAST CELL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; FEMALE; HIGH RISK PATIENT; HUMAN; HYPOTENSION; INFECTION COMPLICATION; ISCHIALGIA; MALE; MULTICENTER STUDY; MYALGIA; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; REMISSION;

AGED; AMIFOSTINE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; SURVIVAL ANALYSIS;

EID: 67549143802     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.03.027     Document Type: Article

References (40)

1. Rajapaksa R., Ginzton N., Rott L.S., and Greenberg P.L. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 88 (1996) 4275-4287
2. Raza A., Gezer S., Mundle S., Gao X.-Z., Alvi S., Borok R., et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 pts. with myelodysplastic syndromes. Blood 86 (1995) 268-276
3. Yoshida Y., Anzai N., and Kawabata H. Apoptosis in myelodysplasia: a paradox or paradigm. Leuk Res 19 12 (1995) 887-891
4. Raza A., Alvi S., Broady-Robinson L., Showel M., Cartlidge J., Mundel S.D., et al. Cell cycle kinetic studies in 68 pts. with myelodysplastic syndromes following intravenous iodo- and/or bromodeoxyuridine. Exp Hematol 25 (1997) 530-535
5. Kurotaki H., Tsushima Y., Hagai K., and Yagihashi S. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia. Acta Haematol 102 (1999) 115-123
6. Parker J.E., Fishlock K.L., Mijovic A., Czepulkowski B., Pagliuca A., and Mufti G.J. 'Low-risk' myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio pro- versus anti-apoptotic bcl-2-related proteins. Br J Haematol 103 (1998) 1075-1082
7. Farquhar M.J., and Bowen D.T. Oxidative stress and the myelodysplastic syndromes. Int J Hematol 77 (2003) 342-350
8. Capizzi R.L. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin Oncol 26 (1999) 3-21
9. Acosta J.C., Richard C., Delgado M.D., Horita M., Rizzo M.G., Fernández-Luna J.L., et al. Amifostine impairs p53-mediated apoptosis of human myeloid leukemia cells. Mol Cancer Ther 2 (2003) 893-900
10. Khodarev N.N., Kataoka Y., Murley J.S., Weichselbaum R.R., and Grdina D.J. Interaction of amifostine and ionizing radiation on transcriptional patterns of apoptotic genes expressed in human microvascular endothelial cells (HMEC). Int J Radiat Oncol Biol Phys 60 (2004) 553-563
11. List A.F., Heaton R., Glinsmann-Gibson B., and Capizzi R.L. Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity. Semin Oncol 23 (1996) 58-63
12. Klimecki W., Heaton R., Glinsmann-Gibson B., and List A.F. Amifostine suppresses apoptosis in myelodysplastic CD34+ cells and promotes progenitor growth via polyamine-like effects. Blood 90 Suppl. 1 (1997) [abstract 2319]
13. Romano M.F., Lamberti A., Bisogni R., Garbi C., Pagnano A.M., Auletta P., et al. Amfostine inhibits hematopoietic progenitor cell apoptosis by activatig NF-κB/Rel transcription factors. Blood 94 (1999) 4060-4066
14. Invernizzi R., Pecci A., Travaglino E., Gobbi P.G., Malabarba L., Ramajoli I., et al. Clinical and biological effects of treatment with amifostine in myelodysplastic syndromes. Br J Haematol 118 (2002) 246-250
15. Moroni M., Porta C., Invernizzi R., Inzoli A., Bobbio-Pallavicini F., and Bobbio-Pallavicini E. 'Tunel' evidence of reduced bone marrow cells apoptosis in a refractory anemia patient treated with amifostine. Br J Haematol 104 (1999) 424-425
16. Pitini V., Arrigo C., Aloi G., Mesiti M., Righi M., Calapso P., et al. Effect of treatment with amifostine in pts. with myelodysplastic syndromes on clinical outcome and apoptosis in bone marrow. Proc Am Soc Clin Oncol (2001) [abstract 1210]
17. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 (1997) 2079-2088
18. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A.G., Gralnick H.R., et al. Proposal for the classification of the myelodysplastic syndromes. Br J Haematol 51 (1982) 189-199
19. Haase D., Feurig-Buske M., Könemann S., Fonatsch C., Troff C., Verbeek W., et al. Evidence of malignant transformation in acute myeloid leukemia at the level of early hematopoetic stem cells by cytogenetic analysis of CD34+ subpopulations. Blood 86 (1995) 2906-2912
20. Mitelman F. ISCN: Guidelines for cancer cytogenetics. Supplement to an International System for Human Cytogenetic Nomenclature. Basel: S. Karger; 1995.
21. Cheson B.D., Greenberg P.L., Bennett J.M., Lowenberg B., Wijermans P.W., Nimer S.D., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108 (2006) 419-425
22. National Cancer Institute (NCI): Common toxicity criteria. Bethesda, MD, USA: Division of Cancer Treatment, National Cancer Institute; 1988.
23. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
24. Peto R., Pike M.C., Armitage P., Breslow N.E., Cox D.R., Howard S.V., et al. Design and analysis of randomized trials requiring prolonged observation of each patient. II. Analysis example. Br J Cancer 35 (1977) 1-39
25. List A.F., Brasfield F., Heaton R., Glinsmann-Gibson B., Crook L., Raymond T., et al. Stimulation of hematopoiesis by amifostine in pts. with myelodysplastic syndrome. Blood 90 (1997) 3364-3369
26. Bowen D.T., Denzlinger C., Brugger W., Culligan D., Gelly K., Adlakha S., et al. Poor response rate to a continuous schedule of amifostine therapy for 'low/intermediate risk' myelodysplastic pts. Br J Haematol 103 (1998) 785-787
27. Brasfield F.M., Heaton R., Glinsmann-Gibson B., Obregon Y., Talley M., Taetle R., and List A.F. phase I/II trial of subcutaneous amifostine in pts. with myelodysplastic syndrome (MDS) (meeting abstract). Proc Am Soc Clin Oncol 17 (1998) [abstract 13]
28. De Castro C.M., Gockermann J.P., Moore J.O., Hartung C., and Misuraca J. Treatment of myelodysplastic syndrome (MDS) with amifostine. Leuk Res 23 (1999) 77 [abstract 204]
29. Denzlinger C., Benz D., Gelly K., Hepburn M., Brugger W., Kanz L., et al. Amifostine for myelodysplastic syndromes: poor response rate to a continuous schedule. Ann Hematol Suppl. 2 (1998) 56 [abstract 220]
30. Galanopoulos A., Kritikou-Griva E., Gligori J., Michalis E., Grigoraki V., Marinakis T., et al. Treatment of pts. with myelodysplastic syndrome with amifostine. Leuk Res 25 (2001) 665-671
31. Grossi A., Fabbri A., Santini V., Leoni F., Nozzoli C., Longo G., et al. Amifostine in the treatment of low-risk myelodysplastic syndromes. Haematologica 85 (2000) 367-371
32. Hoffmann W.-K., Seipelt G., Ottmann O.G., Kalina U., Koschmieder S., Brücher J., et al. Effect of treatment with amifostine used as a single agent in pts. with refractory anemia on clinical outcome and serum tumor necrosis factor α levels. Ann Hematol 79 (2000) 255-258
33. Jarchum G., Ryser R., Bove V., Garcia J., Minoldo D., Heller V., et al. Treatment of myelodysplastic syndrome (MDS) with amifostine (AMF). Blood 90 Suppl. 288b (1997) [abstract 4041]
34. Kempin S., Sirott M., Cecchi G., Irwin D., Gee T., Stepan D., et al. Phase II study of amifostine for the treatment of the myelodysplastic syndrome (MDS) (meeting abstract). Proc Am Soc Clin Oncol 18 (1998) [abstract 108]
35. Ribeiro E., Lima C.S., Metze K., Souca C., and Lorand-Metze I. Changes in hematopoietic precursors after treatment of low-risk myelodysplasia with amifostine. In Vivo 17 (2003) 181-184
36. Tefferi A., Elliott M., Steensma D.P., Hook C.C., Dispenzieria A., Hanson C.A., et al. Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome. Leuk Res 25 (2001) 183-185
37. Terebelo H., Marsico D., Shurafa M., and Karanes C. A Phase II trial of amifostine in pts. with advanced myelodysplastic syndromes (meeting abstract). ASCO (1999) [abstract 82]
38. Viniou N., Terpos E., Galanopoulos A., Kritikou-Griva E., Akel S., Michalis E., et al. Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response. Ann Hematol 81 (2002) 182-186
39. Petti M.C., Latagliata R., Breccia M., Alimena G., Spadea A., D'Andrea M., et al. Spontaneous remission in adult pts. with de novo myelodysplastic syndrome: a possible event. Haematologica 12 (2001) 1277-1280
40. Yilmaz A., Kaufmann C.C., Binder C., Wörmann B., and Haase D. Effects of amifostine in a patient with advanced-stage myelodysplastic syndrome. Ann Hematol 80 (2001) 53-57